These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

991 related items for PubMed ID: 18036082

  • 1. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects.
    Lemoine P, Nir T, Laudon M, Zisapel N.
    J Sleep Res; 2007 Dec; 16(4):372-80. PubMed ID: 18036082
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes.
    Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, Zisapel N.
    Curr Med Res Opin; 2007 Oct; 23(10):2597-605. PubMed ID: 17875243
    [Abstract] [Full Text] [Related]

  • 3. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia.
    Luthringer R, Muzet M, Zisapel N, Staner L.
    Int Clin Psychopharmacol; 2009 Sep; 24(5):239-49. PubMed ID: 19584739
    [Abstract] [Full Text] [Related]

  • 4. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia.
    Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P.
    Sleep Med; 2006 Jun; 7(4):312-8. PubMed ID: 16709464
    [Abstract] [Full Text] [Related]

  • 5. [Controlled release melatonin (Circadin) in the treatment of insomnia in older patients: efficacy and safety in patients with history of use and non-use of hypnotic drugs].
    Zisapel N.
    Harefuah; 2009 May; 148(5):337-41, 348. PubMed ID: 19630367
    [Abstract] [Full Text] [Related]

  • 6. Cross-cultural validation of the Leeds sleep evaluation questionnaire (LSEQ) in insomnia patients.
    Tarrasch R, Laudon M, Zisapel N.
    Hum Psychopharmacol; 2003 Dec; 18(8):603-10. PubMed ID: 14696019
    [Abstract] [Full Text] [Related]

  • 7. A 2-week efficacy and safety study of gaboxadol and zolpidem using electronic diaries in primary insomnia outpatients.
    Hajak G, Hedner J, Eglin M, Loft H, Stórustovu SI, Lütolf S, Lundahl J, Gaboxadol Study 99775 Group.
    Sleep Med; 2009 Aug; 10(7):705-12. PubMed ID: 19346160
    [Abstract] [Full Text] [Related]

  • 8. Effect of melatonin-rich night-time milk on sleep and activity in elderly institutionalized subjects.
    Valtonen M, Niskanen L, Kangas AP, Koskinen T.
    Nord J Psychiatry; 2005 Aug; 59(3):217-21. PubMed ID: 16195124
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
    Roth T, Soubrane C, Titeux L, Walsh JK, Zoladult Study Group.
    Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
    [Abstract] [Full Text] [Related]

  • 10. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response.
    Wade AG, Crawford G, Ford I, McConnachie A, Nir T, Laudon M, Zisapel N.
    Curr Med Res Opin; 2011 Jan; 27(1):87-98. PubMed ID: 21091391
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of modified-release indiplon in elderly patients with chronic insomnia: results of a 2-week double-blind, placebo-controlled trial.
    Lydiard RB, Lankford DA, Seiden DJ, Landin R, Farber R, Walsh JK.
    J Clin Sleep Med; 2006 Jul 15; 2(3):309-15. PubMed ID: 17561543
    [Abstract] [Full Text] [Related]

  • 12. Ramelteon for the treatment of insomnia.
    Borja NL, Daniel KL.
    Clin Ther; 2006 Oct 15; 28(10):1540-55. PubMed ID: 17157111
    [Abstract] [Full Text] [Related]

  • 13. Sleep complaints: Whenever possible, avoid the use of sleeping pills.
    Prescrire Int; 2008 Oct 15; 17(97):206-12. PubMed ID: 19536941
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients.
    Walsh JK, Soubrane C, Roth T.
    Am J Geriatr Psychiatry; 2008 Jan 15; 16(1):44-57. PubMed ID: 18165461
    [Abstract] [Full Text] [Related]

  • 15. Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double-blind randomized clinical trial.
    Peles E, Hetzroni T, Bar-Hamburger R, Adelson M, Schreiber S.
    Addiction; 2007 Dec 15; 102(12):1947-53. PubMed ID: 17916225
    [Abstract] [Full Text] [Related]

  • 16. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers.
    Otmani S, Demazières A, Staner C, Jacob N, Nir T, Zisapel N, Staner L.
    Hum Psychopharmacol; 2008 Dec 15; 23(8):693-705. PubMed ID: 18763235
    [Abstract] [Full Text] [Related]

  • 17. A polysomnography study of eszopiclone in elderly patients with insomnia.
    McCall WV, Erman M, Krystal AD, Rosenberg R, Scharf M, Zammit GK, Wessel T.
    Curr Med Res Opin; 2006 Sep 15; 22(9):1633-42. PubMed ID: 16968566
    [Abstract] [Full Text] [Related]

  • 18. Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo-controlled study.
    Braam W, Didden R, Smits M, Curfs L.
    J Intellect Disabil Res; 2008 Mar 15; 52(Pt 3):256-64. PubMed ID: 18261024
    [Abstract] [Full Text] [Related]

  • 19. The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients.
    Walsh JK, Thacker S, Knowles LJ, Tasker T, Hunneyball IM.
    Sleep Med; 2009 Sep 15; 10(8):859-64. PubMed ID: 19345644
    [Abstract] [Full Text] [Related]

  • 20. A double blind-placebo controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly.
    Cardinali DP, Gvozdenovich E, Kaplan MR, Fainstein I, Shifis HA, Pérez Lloret S, Albornoz L, Negri A.
    Neuro Endocrinol Lett; 2002 Feb 15; 23(1):55-60. PubMed ID: 11880863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.